BioSpace
Avsnitt

Beyond the needle: The future of intratumoral therapy

BioSpace
Dela

In this episode of Denatured, you’ll hear from Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak, president, CEO and board director at Candel Therapeutics. We explore how intratumoral therapies trigger systemic anti-cancer immunity from a local injection, and redefine a foundational platform in immuno-oncology.

Host

Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Lewis Bender, President & CEO, Intensity Therapeutics

Paul-Peter Tak, President, CEO and Board Director, Candel Therapeutics

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.



Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör BioSpace. Innehållet i podden är skapat av BioSpace och inte av, eller tillsammans med, Poddtoppen.